Forward Looking Statement

This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All of the statements in this presentation, whether written or oral, that refer to expected or anticipated future actions and results of NEMUS Bioscience, Inc. (NEMUS) are forward-looking statements. These forward-looking statements reflect the beliefs and expectations of the management of NEMUS as of the date of this presentation. NEMUS cannot give any assurance that such forward-looking statements will prove to be correct. The reader is cautioned not to place undue reliance on these forward-looking statements.

The information provided in this presentation does not identify or include any risk or exposures, of NEMUS that would materially adversely affect the performance or risk of the company. For a description of the risks and uncertainties related to the business of NEMUS, see our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission on March 27, 2015 and our subsequent periodic reports filed with the Securities and Exchange Commission.

All information contained in this presentation is provided as of the date of the presentation and is subject to change without notice. Neither NEMUS, nor any other person undertakes any obligation to update or revise publicly any of the forward-looking statements set out herein, whether as a result of new information, future events or otherwise, except as required by law. This presentation does not convey an offer of any type and is not intended to be, and should not be construed as, an offer to sell, or the solicitation of an offer to buy, any securities of NEMUS.
Company Overview

NEMUS Bioscience is a publicly traded, life-science biotech company, developing regulatory-approved, cannabinoid-based therapies, for a spectrum of diseases, especially those of unmet medical need.

<table>
<thead>
<tr>
<th>OTCQB</th>
<th>NMUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Price (10/2/15)</td>
<td>$0.70 (15 day historical ave.)</td>
</tr>
<tr>
<td>Market Cap (10/2/15)</td>
<td>$12.65 M</td>
</tr>
<tr>
<td>Shares Outstanding</td>
<td>18.1 M common &amp; 5000 PS, 24.3M if 100% converted</td>
</tr>
<tr>
<td>% Ownership by Directors &amp; Employees</td>
<td>23.2% shares 1.13 M options</td>
</tr>
<tr>
<td>Warrants Outstanding</td>
<td>10.6 M (Avg. Strike @ $1.15)</td>
</tr>
<tr>
<td>Founded</td>
<td>2012</td>
</tr>
<tr>
<td>Base of Operations</td>
<td>Costa Mesa, California &amp; Oxford, Mississippi</td>
</tr>
</tbody>
</table>
NEMUS Investment Highlights

• Proprietary product pipeline led by a new chemical entity, a pro-drug of tetrahydrocannabinol or THC (NEMUS product candidate: NB1111)

• Patent issued for composition of matter, production, and methods of use using a variety of formulations/combinations

• The lead compound, NB1111 is a first-in-class treatment for glaucoma

• NEMUS is the only partner of the University of Mississippi for discovery, research and commercialization of cannabinoid-based medicines

• The University of Mississippi is the only U.S. entity authorized by the Federal government since 1968 to cultivate cannabis for research for the study of over 100 cannabinoid molecules in the plant

• NEMUS management team has proven track-record in drug research, pharmaceutical & biotech development, and public company experience on a global scale
Recent Milestones

• August, 2015: Completion of Series B $5 million financing round

• September, 2015: Robert N. Weinreb, globally recognized glaucoma expert joins NEMUS Scientific Advisory Board; Chairs Ophthalmology Board

• September, 2015: Testing completed of ocular delivery vehicle for targeted once-daily dosing of lead NEMUS compound for glaucoma (NB1111; prodrug of THC)

• October, 2015: Testing continues of cannabidiol (CBD) prodrugs designed for ophthalmic and systemic use

• October, 2015: NEMUS partners with Atheln to advance multiple development programs; Dr. Judy Gordon, pre-eminent ophthalmology regulatory expert to oversee NEMUS ophthalmology FDA relationship

• October, 2015: rabbit glaucoma study initiated assessing vehicle delivery of NB1111 in an animal disease model to assess half-life, efficacy, and safety
Currently approved cannabinoids have poor bioavailability & poorly predictable pharmacokinetics

Oral cannabinoids (both pill and spray delivery mechanisms) are subject to high patient-to-patient variability

- Metabolism can vary based on an individual’s genetic metabolic profile
- Plasma levels can be influenced by other medications
- Drug levels impacted by what a patient has eaten

- “Due to extensive first-pass metabolism and high lipid solubility, a fraction of the drug reaches the circulation”\(^1\)
- “The pharmacologic effects of Marinol are dose-related and subject to considerable inter-patient variability”\(^1\)
- “Intoxication type reactions appear dose-related due to great inter-patient drug level variability”\(^2\)
- “The pharmacokinetic data show great inter-subject variability”\(^3\)

NEMUS will capitalize on the use of proprietary formulations that could allow for alternative delivery methods

---

1) Marinol Summary Basis of Approval
2) Sativex Product Labelling - Black Box Warning
3) Sativex Product Labelling
Goal: Predictable Cannabinoid Bioavailability & Pharmacokinetics

NEMUS has licensed a new chemical entity and formulations that have shown improved delivery of cannabinoids in pre-clinical testing.

<table>
<thead>
<tr>
<th>Ocular</th>
<th>Trans-mucosal</th>
<th>Rectal</th>
</tr>
</thead>
</table>

A Comparison of THC Plasma Concentrations From ProDrug THC Suppository* vs. Marinol in Humans

All NEMUS licensed delivery options avoid bioavailability-compromising first-pass metabolism by the liver.

Source: NEMUS Internal Data -
The Single Convention treaty requires member nations (over 100) to designate a single entity eligible to cultivate cannabis for research purposes.

The University of Mississippi is the only entity in the US that is authorized by NIDA and the DEA to cultivate cannabis on behalf of the federal government.

The University of Mississippi has a continuous 35+ year regulatory history in dealing with FDA, DEA, NIDA, NIH, etc.

A January 22, 2013, U.S. Court of Appeals for the District of Columbia Circuit upheld DEA’s continued classification of cannabis as a Schedule I controlled substance, subject to stringent regulation.

In March, 2015, NIDA once again granted the 5yr contract to the University.

This also presents hurdles to the development, commercialization and importation of products into the U.S.
NEMUS and the University of Mississippi: Over 45 years of Intellectual Capital in Cannabinoid Chemistry

EXCLUSIVE AGREEMENTS BETWEEN NEMUS AND THE UNIVERSITY OF MISSISSIPPI

Recurring Option Agreement for the NCE

Method of Delivery Agreements
UM 4718 – Suppository Delivery of Dronabinol Hemisuccinate (DHS) – Exclusive worldwide license to intellectual property, proprietary data and know-how related to a suppository dosage form containing Dronabinol Hemisuccinate and other esters. (“NPC 4718”) and development through FDA.

UM 1490 – TransMucosal Delivery of Cannabinoids – Exclusive worldwide license to intellectual property, proprietary data and know-how related to transmucosal delivery of cannabinoids (“UM1490”) and development through FDA.

UM 8790 – Ocular Delivery of Cannabinoids – Exclusive worldwide license to intellectual property, proprietary data and know-how related to ocular delivery of cannabinoids (“UM 8790”) and development through FDA.

Research Agreement
UM 5070 – MRSA – Exclusive worldwide option to license intellectual property, proprietary data and know-how related to the treatment of methicillin-resistant Staphylococcus aureus infections using cannabinoids (“UM 5070”) and development through FDA.

CBD Pro-drug – Exclusive worldwide option to license intellectual property, proprietary data and know-how on the use of a proprietary cannabidiol prodrug.
Key Partnership With University Of Mississippi and International Thought Leaders in Ophthalmology

- NEMUS has licensed the rights to a novel THC pro-drug. The recently issued patent contains claims for composition of matter, formulation, delivery and method of use
- NEMUS has entered into multiple license agreements and a research agreement for specific formulations and corresponding delivery methods
- NEMUS has perpetual, worldwide exclusivity for all compounds and targets we are working on with UM
- UM provides over 45 years of knowledge and experience in the science of cannabinoids
- NEMUS has access to a large number of globally recognized scientists and thought leaders in cannabinoid medicine
- Robert Weinreb, MD; Distinguished Professor of Ophthalmology; renown expert in glaucoma
- Dr. Judy Gordon; pre-eminent regulatory specialist in ophthalmology
NEMUS Licensed the Rights from UOM

US Patent: 8,809,261

- Issued Aug 19, 2014 to University of Mississippi.
- Compositions containing delta-9-THC-amino acid esters and process of preparation.
- Consists of 66 claims:
  - Amino acid, hemi-succinate, hemi-gluturate forms of THC.
  - Preparation of several forms of amino acid, hemi-succinate, and hemi-gluturate forms of THC.
  - Compositions that contain forms of amino acid, hemisuccinate, and hemi-gluturate forms of THC.
  - “Any condition that can respond to the prodrugs of delta-9-THC in a pharmaceutically acceptable carrier.”
Development Pipeline: Near-, Intermediate-, Longer-Term Projects; CBD formulations in development

Target indications are multi-billion dollar global markets of urgent medical need

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Target</th>
<th>Research</th>
<th>Pre-clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>NB1111</td>
<td>Glaucoma/Ophthalmology Targets</td>
<td></td>
<td></td>
<td>Topical Ocular Delivery</td>
<td>Buccal Patch or Suppository Delivery</td>
<td></td>
</tr>
<tr>
<td>NB2221</td>
<td>Multiple Sclerosis Spasticity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NB51R1</td>
<td>Anxiety</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NB23R1</td>
<td>Epilepsy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NB31R1</td>
<td>Methicillin-Resistant Staph Aureus</td>
<td></td>
<td>Cannabinoid</td>
<td>Cocktail</td>
<td>Anti-Infective</td>
<td></td>
</tr>
</tbody>
</table>

In parallel to the THC program which is entering preclinical IND-enabling studies, NEMUS is also preparing development tracts for other biologically active cannabinoids, including but not limited to CBD.
How the world is seen with glaucoma

Normal field of vision

Field of vision decreased from glaucoma
Our Strategic Asset Management evaluation concluded that glaucoma was the most attractive first target

- $8 billion globally and growing with aging populations
- A leading cause of blindness in the US
- $2.3 billion US market (32 MM Rx)
- Regulatory pathway well-defined
- Regulatory strategy: Potential for “urgent medical need” and “breakthrough therapy” FDA designations;
- Glaucoma as a “Non-responder” market presents greater opportunities; >50% of patients on 2 or more Rx
- Cannabinoids have shown neuroprotective qualities in vitro and in vivo (multiple animal species)
- Licensing and acquisitions in the glaucoma market occur predominantly earlier in development (pre-clin, phase 1)
Topical ocular treatment with a proprietary THC prodrug could bring a new therapeutic class directly to the target organ, avoiding systemic exposure.

FEATURES OF THE NEMUS LEAD COMPOUND

• Penetrates all chambers of the eye
• Produces a reduction in Intra-Ocular Pressure (IOP) in glaucoma animal model (THC has been shown to lower IOP in previous human testing)
• Reduction of IOP is the only proven method to treat glaucoma
• QD dosing objective using new delivery mechanism
• Potentially first medication to exert direct neuroprotection of the optic nerve (retinal ganglion cells; RGCs) by inhibiting apoptosis pathway
• Neuroprotection is the “holy grail” of glaucoma

The proprietary formulation allows THC to be absorbed across membranes that are normally barriers to absorption.
Only NB1111 addresses multiple MOAs

<table>
<thead>
<tr>
<th>Therapy Class</th>
<th>Increased flow</th>
<th>Increased flow</th>
<th>Decreased fluid production</th>
<th>Direct neuroprotective qualities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mechanism of Action (MOA)</td>
<td>Trabecular mesh</td>
<td>uveoscleral pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostaglandins (50% mkt share)</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>β- adrenergic blockers (30%)</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>α- adrenergic agonists (10%)</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Carbonic anhydrase inhibitors (&lt;5%)</td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Cholinergic agonists (&lt;5%)</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
</tr>
<tr>
<td>Pro-drug THC (NB1111)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>
THC lowers IOP in humans; predictive animal model consistent with human experience

• Active moiety of NB1111, THC, has been shown to lower IOP in humans
• Testing conducted by universities, NIH, and the US Army
• THC component of proprietary pro-drug lowered IOP in human glaucoma up to 65% in some cases
• The NEMUS prodrug NB1111 achieved a 45%-50% reduction in IOP in a validated rabbit glaucoma model
• Rabbit glaucoma model presented at AAPS meeting November, 2014 by University of Mississippi
• New formulation testing of NB1111 to enhance half-life: QD dosing
THC-val-HS outperforms timolol and pilocarpine in IOP reduction*

Unlike many licensing deals, ophthalmology deals are often done early in development.

Of 408 deals related to ophthalmology revealed in SEC documents, 265 were related to pharmaceuticals, from early to late stage.
Value grows after Phase 1 and again after Phase 2 (ex, glaucoma @ $750MM peak year)
NB1111 Development Timeline: Glaucoma
## Use of proceeds: glaucoma

<table>
<thead>
<tr>
<th>ACTIVITY</th>
<th>PROJECTED COST</th>
</tr>
</thead>
<tbody>
<tr>
<td>CMC*-FORMULATION</td>
<td>$2.6 million</td>
</tr>
<tr>
<td>IND** ENABLING STUDIES &amp; FILING</td>
<td>$3.2 million</td>
</tr>
<tr>
<td>CLINICAL PHASE 1b/2a Study</td>
<td>$1.8 million</td>
</tr>
<tr>
<td><strong>PROJECTED TOTAL</strong></td>
<td><strong>$7.6 million</strong></td>
</tr>
</tbody>
</table>
MRSA has become a global urgent health concern
Methicillin-Resistant Staph Aureus (MRSA)

**MRSA FACTS & CURRENT MEDICAL LANDSCAPE**

- First described in 1961 now a pandemic
- CDC: prevalence of MRSA in ICU setting approaching 60%
- 1960’s: one genetic MRSA mutation/clone; currently six MRSA genetic clones; 15 clones in China
- 2010 hospital survey: 61.8% of patients admitted to ICU were MRSA colonized¹
- 50% of screened patients had healthcare-associated infections¹
- 11,000 deaths annually; 80,000 invasive infections/yr.²
- Annual costs in the US: $3.2 - $4 billion²

¹ Jarvis WR et al; Am J Infect Control 2012; 40(3): 194-200
² Pew Trust MRSA Survey; April 3, 2012
Methicillin-Resistant Staph Aureus (MRSA)

NEMUS is assessing a new class of anti-infectives to combat the threat of antibiotic resistance

CANNABINOID EXPERIENCE IN MRSA

- Select cannabinoids have been known to possess some antibacterial properties
- Anti-bacterial properties can be leveraged to address newly developed strains exhibiting antibiotic resistance to current meds
- NEMUS intends to file IP concerning the use of transmembrane enhancing formulations of cannabinoids to facilitate bacteriocidal activity
- IP is being developed on the use of “drug cocktails” to address certain species of MRSA and other bacterial species so that therapy can be tailored to specific strains, in an effort to lower resistance development going forward

- Antibacterial cannabinoids from Cannabis sativa: a structure-activity study
NEMUS will initially operate through a strategically aligned network of researchers, CMC consulting experts, and specialty service consultants to advance our pipeline projects.

- Strategic direction
- Clinical/regulatory responsibility
- Legal/IP
- Management of partners
- Business development
- Commercialization in selected markets

### Academic Research Partners
- University of Mississippi
- UCSD
- Johns Hopkins
- University of Washington

### Legal/IP Partner
- Develop and execute IP strategy

### Atheln and/or other out-sourced CMO/CRO firm
- Drug development/tech transfer

### API
- Manufacturing

### Pharma/Biotech
- Commercialization Partners
- Out-licensing Assessment
COSMAS N. LYKOS, ESQ – Co-founder, Officer & Board Member – Executive Chairman

Cosmas Lykos co-founded NEMUS in 2012 and has served as its Chairman of the Board of Directors since August 2014. After graduating with Honors from Duke University School of Law in 1993, Mr. Lykos began his career at Gibson Dunn & Crutcher, LLP, an international full-service law firm, as a corporate associate until 1998. From 1998 to 2004, Mr. Lykos served as Vice President of Business Affairs, General Counsel, Secretary and Chief Compliance Officer of RemedyTemp, Inc., a NASDAQ publicly-traded temporary staffing firm with over 250 directly-owned and franchised offices nationwide. From 2004 until 2008, Mr. Lykos served as Vice President of Business Development, Chief Legal Officer, Secretary and Chief Compliance Officer of Oakley, Inc., a NYSE publicly-traded sports and technical eyewear, apparel, accessories and retail company. In January of 2008, he became Co-owner and President of the Optical Shop International, a designer and distributor of licensed eyewear brands, including Chrome Hearts and Blinde, through two wholly-owned foreign subsidiaries with a direct and distributor sales network in over 60 countries around the world. Primary responsibilities included developing and implementing OSI’s vision and strategies and the management of its foreign subsidiaries, sales, legal, human resources, finance and administrative functions. In 2011, Mr. Lykos negotiated and consummated the sale of OSI to its primary licensor, Chrome Hearts LLC and continues to provide consulting services. Mr. Lykos has extensive public and private company board of directors experience. As Chief Compliance and Legal Officer and Secretary of both Oakley, Inc. and RemedyTemp, Inc., Mr. Lykos attended all board of director meetings and board committee meetings. As an angel investor, Mr. Lykos has made minority investments in various private companies and has served on their Board of Directors.
Management

BRIAN MURPHY, MD, MPH, MBA – Chief Executive Officer; Chief Medical Officer, Director
Dr. Murphy has almost two decades of experience in drug development and evaluation, both from the academic and industry perspective. He most recently served as the CMO of Eiger Biosciences. Previously, Dr. Murphy was CMO at Valeant Pharmaceuticals International (VRX) where his responsibilities also included oversight of Global Medical Affairs and Pharmacovigilance. Dr. Murphy also served as Medical Director, then VP of Marketing and Commercial Strategy of Hepatology for InterMune, Inc. (ITMN). Prior to InterMune, Dr. Murphy was Medical Director of North America for Antivirals/Interferons at Hoffmann-LaRoche. Murphy is board-certified in internal medicine and completed his residency at Tufts-New England Medical Center. He went on to complete parallel fellowship tracts at Harvard Medical School and the Massachusetts General Hospital. Dr. Murphy earned his MD, MPH (general public health), and MS (pharmacology) degrees from New York Medical College and is a graduate of the Harvard School of Public Health (MPH in Health Policy and Management). He earned his MBA at the Columbia University Graduate School of Business.

LIZ BERECZ, MA, CPA - Chief Financial Officer
Elizabeth Berecz is a seasoned financial executive with over 20 years of experience holding senior level positions in both private and public companies. She has proven success in leading strategic planning, financial reporting, and global system implementations for companies of various sizes. Liz started her career at Price Waterhouse Silicon Valley where she spent five years auditing several high profile public companies in the technology industry. She then spent 10 years holding key leadership positions in various publicly held Companies including Quantum Corporation (Corporate Controller), Business Objects (VP Finance and Administration), and Excite (VP Finance), followed by 10 years of key leadership roles in privately held Companies including CFO positions with Optical Shop International, StarTrac Inc., Power Balance Technologies, Inc. and most recently Bentley Mills, Inc. She also serves as an Adjunct Professor of Accounting and Finance at the University of San Francisco. Elizabeth received her BA in Economics from Stanford University and a MA in Sports Management from University of San Francisco.
BOD & Strategic Advisors

DOUGLAS S. INGRAM, ESQ
Board of Directors – Vice Chairman, Chairman of Compensation Committee
25 year senior executive in healthcare, Past President of Allergan, former Attorney at Gibson, Dunn & Crutcher, LLP. *Summa cum laude* and Order of the Coif graduate of the Univ. of Arizona school of law.

TOM GEORGE
Board of Directors – Chairman of Audit Committee
30 year senior executive in corporate finance and accounting (Deckers Brands, Ophthonix, Oakley).

JERRY MCLAUGHLIN, MBA
Strategic Advisor, Board of Directors - Member
25 year veteran executive in pharmaceutical medical device and healthcare related industries (AgeneBio, Merck, Endo Pharma, Villanova University, Dickinson College).

MAHMOUD A. ELSOHLY, PHD
Scientific Advisor
World’s foremost expert on the science of cannabinoids. 300+ scientific publications. Research professor at The University of Mississippi.

Robert N. Weinreb, M.D.
Scientific Advisor
Chair, Ophthalmology Advisory Board
Globally recognized expert on glaucoma and eye diseases. 1000+ scientific publications. Distinguished Professor of Ophthalmology; University of California San Diego

Judy Gordon, D.V.M..
Scientific Advisor
Ophthalmology Regulatory Specialist
Pre-eminent regulatory specialist with internationally recognized expertise in regulatory filings at FDA/EMA for NCE’s for use in the ophthalmology space.
Contact

Company
Brian Murphy, MD, MPH, MBA
CEO - CMO
Tel: 949-355-1140
brian@nemusbio.com

Investor Relations
Mike Cole, Vice President
MZ North America
Tel: 949-259-4988
mike.cole@mzgroup.us
www.mzgroup.us

650 Town Center Drive, Suite 1770
Costa Mesa, CA 92626
(949) 396-0330
hello@nemusbio.com
www.nemusbioscience.com